PATENT CLAIM ANALYSIS

Application Number: 16218353
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["514", "020800"]

Abstract:
The present disclosure provides pharmaceutical compositions and methods thereof for the treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept.

Claim (Index 14):
The method of  claim 1 , wherein the administering by intravitreal injection is a one-time administration.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 98.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15851650', '14281749', '13868453', '15058938', '15602096']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7322675489338724
- 35 USC 102 Novelty (BERT): 0.5118941356475385
- Combined Prediction Score: 0.7102302076052389
- Mean Citation Score: 245.46073
- Max Citation Score: 280.33154
- Similarity Product: 202.22345967876203

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test